Insider Selling: United Therapeutics (NASDAQ:UTHR) Director Sells $23,711.50 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Jan Malcolm sold 50 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $474.23, for a total value of $23,711.50. Following the completion of the transaction, the director owned 270 shares in the company, valued at approximately $128,042.10. The trade was a 15.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Jan Malcolm also recently made the following trade(s):

• On Friday, January 16th, Jan Malcolm sold 50 shares of United Therapeutics stock. The stock was sold at an average price of $460.98, for a total value of $23,049.00.
• On Monday, January 5th, Jan Malcolm sold 50 shares of United Therapeutics stock. The shares were sold at an average price of $495.01, for a total transaction of $24,750.50.
• On Tuesday, December 23rd, Jan Malcolm sold 50 shares of United Therapeutics stock. The shares were sold at an average price of $512.12, for a total transaction of $25,606.00.
• On Thursday, December 11th, Jan Malcolm sold 50 shares of United Therapeutics stock. The stock was sold at an average price of $482.98, for a total transaction of $24,149.00.

United Therapeutics Price Performance

UTHR opened at $478.93 on Friday. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $519.99. The firm has a market capitalization of $20.62 billion, a PE ratio of 18.15, a P/E/G ratio of 2.57 and a beta of 0.85. The company’s 50-day moving average is $486.76 and its 200 day moving average is $425.24.

Institutional Trading of United Therapeutics

Hedge funds have recently made changes to their positions in the company. Torren Management LLC bought a new position in shares of United Therapeutics during the 4th quarter worth $26,000. Activest Wealth Management lifted its holdings in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the last quarter. Entrust Financial LLC bought a new position in United Therapeutics during the fourth quarter worth about $31,000. Wilmington Savings Fund Society FSB increased its stake in shares of United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares in the last quarter. Finally, Harbor Capital Advisors Inc. purchased a new position in shares of United Therapeutics in the fourth quarter worth about $48,000. 94.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. UBS Group raised their price objective on United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. HC Wainwright raised their price target on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $575.00 price objective on shares of United Therapeutics in a research report on Wednesday, November 19th. Royal Bank Of Canada lifted their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. Finally, Morgan Stanley set a $447.00 target price on United Therapeutics in a research note on Wednesday, October 29th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $509.50.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.